Patents by Inventor SILVIA MENEGATTI

SILVIA MENEGATTI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune Cells Defective for SOCS1
    Publication number: 20230303974
    Abstract: The present invention relates to an engineered immune cell defective for SOCS1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of SOCS1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 28, 2023
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale
    Inventors: Laurie Menger, Silvia Menegatti, Sebastian Amigorena
  • IMMUNOLOGICAL SIGNATURES AND PARAMETERS PREDICTING THERAPEUTIC RESPONSES TO ANTI-TNF THERAPY
    Publication number: 20220128572
    Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.
    Type: Application
    Filed: January 3, 2022
    Publication date: April 28, 2022
    Applicants: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE DE PARIS
    Inventors: LARS ROGGE, SILVIA MENEGATTI, MAXIME DOUGADOS, ELISABETTA BIANCHI
  • Immunological signatures and parameters predicting therapeutic responses to anti-TNF therapy
    Patent number: 11249090
    Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 15, 2022
    Assignees: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE DE PARIS
    Inventors: Lars Rogge, Silvia Menegatti, Maxime Dougados, Elisabetta Bianchi
  • IMMUNOLOGICAL SIGNATURES AND PARAMETERS PREDICTING THERAPEUTIC RESPONSES TO ANTI-TNF THERAPY
    Publication number: 20180267058
    Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.
    Type: Application
    Filed: September 27, 2016
    Publication date: September 20, 2018
    Inventors: LARS ROGGE, SILVIA MENEGATTI, MAXIME DOUGADOS, ELISABETTA BIANCHI